Lupin unveils Cyanocobalamin Nasal Spray in US

It is indicated for prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements more than normal.

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-02-04 11:00 GMT   |   Update On 2024-03-21 16:21 GMT
Advertisement

Mumbai: Pharma major Lupin Limited has announced the launch of Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device), after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device) is a generic equivalent of Nascobal Nasal Spray, 500 mcg/spray of Par Pharmaceutical, Inc.

It is indicated for:

Advertisement
  • vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement
  • treatment of adult patients with dietary, drug-induced, or malabsorption related vitamin B12 deficiency not due to pernicious anemia
  • prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements more than normal.

Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 59 million in the U.S. (IQVIA MAT December 2023).

Read also: Lupin Gets CDSCO Panel Nod to Study FDC of Fluticasone, Glycopyrronium, Vilanterol Inhalation Powder

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin Digital Health, American College of Cardiology introduce Digital Therapeutics Certificate for Cardiologists in India

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News